Results of an extensive Phase II programme for the treatment of deep vein thrombosis and its secondary prevention with the oral, direct factor Xa inhibitor Rivaroxaban (BAY 59-7939), currently under development by Bayer and Johnson & Johnson, will be presented on September 5, 2006 at the World Congress of Cardiology 2006 in Barcelona, Spain. Live on the internet Bayer AG will be broadcasting a conference call hosted for investors and analysts on this occasion:
Tuesday, September 5, 2006 Investor Conference Call 6:00 p.m. CEST to review Rivaroxaban data presented at the World Congress of Cardiology 2006
with
Dr. Gunnar Riemann, President of the Pharmaceuticals Division Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development Dr. Alexander Rosar, Head of Investor Relations
A recording of the conference call will be available as from September 6 at approx. 9:00 a.m. CEST (7:00 a.m. GMT).
The audio transmission and recording can be accessed on these sites: English: http://www.investor.bayer.com German: http://www.investor.bayer.de
Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com
If you have any questions, please contact:
Dr. Alexander Rosar (+49-214-30-81013) Dr. Juergen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Ilia Kürten (+49-214-30-35426) Ute Menke (+49-214-30-33021) Judith Nestmann (+49-214-30-66836) Dr. Olaf Weber (+49-214-30-33567)
--- End of Message --- WKN: 575200; ISIN: DE0005752000; Index: CDAX, DAX, HDAX, Prime All Share; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Börse Berlin Bremen, Amtlicher Markt in Börse Düsseldorf, Amtlicher Markt in Hanseatische Wertpapierbörse zu Hamburg, Amtlicher Markt in Niedersächsische Börse zu Hannover, Amtlicher Markt in Bayerische Börse München, Amtlicher Markt in Börse Stuttgart;
